Granules

completed

Granules India Limited (Granules or the company) is a medium-sized generic pharmaceutical company based in Hyderabad, State of Andhra Pradesh, India. It is a leading manufacturer of pharmaceutical formulation intermediates (PFIs). PFIs are blends of single or multiple active pharmaceutical ingredients (APIs) and excipients, ready to be compressed into tablets or filled into capsules. Granules also manufactures and sells APIs and formulations in over 35 countries globally. The company focuses mainly on a portfolio of high-volume drugs that have experienced post patent price erosions in the past (e.g. ibuprofen, paracetamol, aspirin, etc.). Granules has grown from one plant (Bonthapally) in 1987 to three (a new facility at the Bonthapally site plus plants at Gagilapur, and Jeedimetla, constructed in 2003 and 2006 respectively). A fourth plant is currently under construction at the 20-acre Gagilapur campus for the production of tablets; it is expected to be operational by June 2007. The company’s expansion plan is to leverage on its strength in low cost, large volume manufacturing and move up the industry value chain by expanding its product basket to include 8-10 new products each year, and manufacturing select, higher margin prescription drugs for the US and EU markets. To do so, Granules is in the process of setting up a new API and formulations facility and related product developments and registrations.